Harbinger Health, a Cambridge, MA-based biotechnology company focused on cancer screening and detection, raised $140M in Series B funding.
The round wad led by Flagship Pioneering, Pictet, Partners Investment, and Catalyst, among other investors.
The company intends to use the funds for the completion of its Cancer ORigin Epigenetics-Harbinger Health (CORE-HH) 10,000-participant clinical study of its novel blood-based cancer screening platform, develop its two-tier testing model, expand its data science and commercial teams and capabilities, and initiate additional clinical studies in high-risk populations.
Led by Stephen Hahn, M.D., and CEO, Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Its platform, HarbingerHx, leverages machine learning, proprietary insights into the molecular biology of cancer’s origins, and growing datasets to develop insights that maximize clinical informativeness. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020.
The company expects to launch its first product – a laboratory developed test (LDT) for the detection of early cancer – in 2025.